We are live on !
Find out more
Third Rock Ventures Portfolio holdings
AUM
$1.07B
Turnover
20%
1-Year Est. Return
170.23%
This Fund
S&P 500
This Quarter Est. Return
+4.8%
1 Year Est. Return
+170.23%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$857M
AUM Growth
+$389M
(+83%)
Cap. Flow
+$366M
Cap. Flow % of AUM
Cap. Flow %
42.68%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
2
Increased
–
Reduced
2
Closed
–
Avg Time Held
0.5
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sage Therapeutics
SAGE
|
+$338M |
| 2 |
Larimar Therapeutics
LRMR
|
+$106M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
bluebird bio
BLUE
|
+$42.8M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$35.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Sage Therapeutics
SAGE
| $368M | 42.92% |
+11,681,008
| New | +$338M |
2014 Q3
0 quarters
|
|
|
2
Agios Pharmaceuticals
AGIO
$1.81B
| $188M | 21.97% |
3,070,090
-825,000
| -21% | -$35.6M |
2013 Q4
3 quarters
|
|
|
3
Larimar Therapeutics
LRMR
$256M
| $110M | 12.84% |
+466,837
| New | +$106M |
2014 Q3
0 quarters
|
|
|
FMI
4
DELISTED
Foundation Medicine, Inc.
FMI
| $93.4M | 10.9% |
4,927,234
| – | – |
2013 Q4
3 quarters
|
|
5
DELISTED
Carisma Therapeutics
CARM
| $53.9M | 6.29% |
242,080
| – | – |
2014 Q1
2 quarters
|
|
|
6
DELISTED
bluebird bio
BLUE
| $43.6M | 5.09% |
93,802
-92,788
| -50% | -$42.8M |
2013 Q4
3 quarters
|
|
Similar funds
AH
GHF
TCM
Third Rock Ventures's Q3 2014 Portfolio in Review
As of Q3 2014, Third Rock Ventures held 6 positions worth $857M, up 83% from $468M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Third Rock Ventures deployed $366M of net new capital in Q3 2014, opening 2 new positions. Its largest new stake was Sage Therapeutics: 11,681,008 shares worth $368M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was bluebird bio, an estimated $42.8M trimmed.
- Third Rock Ventures's largest Q3 2014 buy was Sage Therapeutics: 11,681,008 shares worth $368M.
- Third Rock Ventures's biggest Q3 2014 reduction was bluebird bio, cutting an estimated $42.8M.
- Third Rock Ventures's ten largest holdings make up 100% of its $857M portfolio in Q3 2014.
- Third Rock Ventures opened 2 new positions and closed 0 in Q3 2014.
- Third Rock Ventures's portfolio value rose 83% quarter-over-quarter to $857M.
Based on Third Rock Ventures's 13F filing for Q3 2014, filed 22 Oct 2014.